MYDENTALWIG™: AN INTEGRATED TECHNOLOGY ECOSYSTEM
From the mouth to intelligence.
MYDENTALWIG is building a vertically integrated technology ecosystem connecting dental innovation, human health, EI (Extraordinary Intelligence), sensing, advanced manufacturing, and intelligent infrastructure — one continuous system, from the smile to the data center.
Please read “EI” – Extraordinary Intelligence – wherever “AI” appears in this website.
“Prevention Is Better Than Cure.”
OFFERING MATRICES: REGULATION D, RULE 506(c) GENERAL SOLICITATION
This initial $21,000,000 ($21 Million usd) financing round is structured as a defined 12-month value-creation and de-risking program. Proceeds are strictly allocated to move our patented intraoral ingestion-sensing technology from its current pre-commercial validation phase into active revenue generation and human clinical pilot tracking.
Dear Lydie,
I am happy to report that the above-described Utility patent application was filed July 24th, 2026.
This is a time-critical opportunity for American innovation. U.S. government investment or grant support for MYDENTALWIG would provide the financial capacity to meet the international patent deadline and secure worldwide protection for this U.S.-developed invention. Our 12-month DentalWig PLUS™ roadmap is already in place, and with timely funding, we can move from roadmap to execution and make our proprietary chip available—strengthening American leadership in this emerging technology.
MYDENTALWIG is a patent-stage health technology company developing DentalWig PLUS™ — Diabetes, an EI²™ (Extraordinary Ingestion Intelligence)-powered ingestion-intelligence platform designed to capture objective eating behavior and correlate ingestion events with continuous metabolic data, with the end-goal to prevent illnesses.
The company is currently at the pre-commercial validation stage. The core investment opportunity is not based on an assumption that every technical and clinical hypothesis has already been proven. Rather, the 12-month development program is designed to systematically validate the critical technical, scientific, clinical, regulatory and commercial assumptions required to commercialize the platform.
Most people:
Continuous Glucose Monitor (CGM)
To ensure highest-level corporate governance, scientific transparency, and long-term asset defensibility, MYDENTALWIG™ maintains an active publication track within premier peer-reviewed scientific journals and medical societies.
Our core technological manuscript—detailing the micro-sensor methodology, edge-AI algorithms, and the integration of objective intraoral ingestion-sensing nodes with downstream continuous glucose monitor (CGM) metrics—is tracking through the following institutional pipelines:
Formal pre-submission technology framework brief cleared initial administrative processing and is officially under active consideration by the ADA Peer Review and Editorial Production teams.
Submission architecture is finalized. Full methodology manuscript routing is scheduled for deployment immediately following the ADA’s November 15, 2026 centralized online portal transition.
This parallel academic deployment de-risks incoming Regulation D, Rule 506(c) private equity tranches. By validating our underlying U.S. Utility Patent Application (Serial No. 19752971) within top-tier clinical metabolism and dental registries, we convert our patent-stage innovations into an internationally recognized, scientifically backed digital health infrastructure asset.
real-time ingestion intelligence
6. SOLUTION
1
User eats → device detects ingestion event
2
Wearable captures context (sleep, stress, activity)
3
CGM records glucose response
4
EI learns personalized metabolic response curve
5
System provides real-time guidance:
10. WHY NOW
11. TAM
| Company type | What they measure |
|---|---|
| Wearables | physiology |
| CGM companies | glucose |
| Food apps | self-report |
| We | real ingestion behavior |
Every validated ingestion event can become part of a longitudinal dataset linking eating behavior, timing, behavioral patterns and physiological response. As the dataset grows, it may improve personalization, model performance and prediction capabilities, potentially creating increasing barriers to entry.
Investors are not being asked to fund an unbounded research project. The $21 million financing is intended to fund a defined 12-month program with identifiable technical, clinical, regulatory, manufacturing and commercial milestones.
Accordingly, the investment opportunity is based not solely on the present concept, but on the enterprise, value expected to be created through successful execution of these measurable milestones.
The missing sensory layer of human metabolism.
Demonstrate that intraoral sensing can reliably generate clinically useful ingestion intelligence and establish the technical foundation for commercialization.
Disease → Symptoms → Diagnosis → Treatment
Food Ingestion → Continuous Physiological Intelligence (CPI) → Prediction → Prevention
MYDENTALWIG is not being presented as an idea accompanied by a roadmap. The Company has established a patented technology thesis, defined its technology architecture, identified the critical technical and clinical assumptions that must be validated, and developed a structured 12-month program to move those assumptions through measurable stages of validation and commercialization.
The proposed $21 million financing is designed to fund this transition—from patented technology and pre-commercial development through technical and human validation, clinical development, product commercialization, initial recurring revenue and the creation of a scalable EI-driven healthcare platform.
Accordingly, the investment thesis is not based solely on the present concept. It is based on the Company’s ability to deploy capital against a defined sequence of technology validation, value-creation and commercialization milestones, with each successful stage intended to reduce risk and increase enterprise value.
20- MYDENTALWIG'S $21 MILLION FINANCING
MYDENTALWIG is not presenting the $21 million financing as capital required simply to pursue an idea. The financing is designed to fund a defined 12-month program encompassing technology development, AI development, sensor engineering, human pilot studies, CGM-integrated validation, clinical development, regulatory preparation, manufacturing infrastructure, commercialization and the creation of proprietary ingestion-intelligence data.
The investment thesis is therefore based on the transformation of MYDENTALWIG from a patent-stage, pre-revenue technology company into a validated, commercially deployable EI-driven healthcare platform with intellectual property, proprietary data, recurring subscription revenue and multiple future applications.
This investment is expected to unlock:
Embedded EI²™ sensor technology licensed to dental professionals for:
The proceeds are intended to transition MYDENTALWIG from a pre-revenue innovation company into a recurring revenue EI healthcare platform with multiple revenue streams, significantly increasing enterprise value through commercial traction, proprietary data assets, intellectual property expansion, and scalable subscription-based recurring revenue.
for verified accredited investors only through 3rd party. Minimum investment: $1,000,000 usd
for accredited and non-accredited investors verified by 3rd party. Minimum investment: $1,000 usd up to $5,000,000 usd.
How does investing $21 million today create a company that will be worth substantially more tomorrow: by unlocking specific value-creating milestones that significantly reduce risk and increase the company’s valuation.
The $21 million financing is structured as a value-creation and risk-reduction program.
The objective is to transform MYDENTALWIG through identifiable development stages:
The investment thesis is not that the company has already eliminated technical and clinical risk. The investment thesis is that capital is deployed to eliminate defined categories of risk while simultaneously creating intellectual property, proprietary data, validated technology, commercial infrastructure and recurring revenue.
| Today | $21M program | Result |
|---|---|---|
| Patent filed | Engineering + prototype validation | Technical feasibility |
| Hypothesis | 50–200 user pilot | Human data |
| Conceptual EI | CGM paired dataset | Validated algorithms |
| Prototype-stage | Manufacturing development | Scalable product |
| Pre-revenue | Commercial launch | Revenue |
| No proprietary dataset | Longitudinal ingestion dataset | Data moat |
| Unvalidated prediction | Clinical evidence | Reduced scientific risk |
Significant capital can be committed to transformative technologies before the ultimate commercial product, market scale, or economic outcome has been fully established.
These examples demonstrate an important principle: transformative technology investment is not necessarily limited to companies that have already completed product development, achieved profitability, or eliminated technical uncertainty. Investors provide substantial capital when they believe the underlying technological opportunity is significant and when the capital can be deployed against a defined plan capable of creating substantial additional enterprise value.
| Sources of Funds | Amount (USD) |
|---|---|
| Reg D Rule 506(c) Offering | $21,000,000 |
| Total Sources of Funds | $21,000,000 |
| Source & Uses of Funds | Amount (USD) | % of Total |
|---|---|---|
| Research, Development & Pilot Manufacturing Infrastructure (facility build-out, laboratories, pilot manufacturing equipment, EI infrastructure) | $7,745,000 | 36.9% |
| Personnel & Operations (engineering, manufacturing, EI, administration, facility operations, benefits) | $4,250,000 | 20.2% |
| Product Development & Clinical Validation | $3,500,000 | 16.7% |
| Regulatory, Intellectual Property & Professional Services | $2,250,000 | 10.7% |
| Sales, Strategic Partnerships & Business Development | $1,250,000 | 6.0% |
| Working Capital & Contingency Reserve | $2,005,000 | 9.5% |
| Total Uses of Funds | $21,000,000 | 100.0% |
| CATEGORY | DETAILS |
|---|---|
| Offering Type | Rule 506(c) Private Placement (Reg D exemption) |
| Minimum Investment | $1,000,000 per investor at $1 billion Pre-money Valuation (Current Reg CF terms) |
| Accredited Investor | – Individual net worth > $1M (excluding primary residence), or annual income > $200k (or $300k with spouse) in the last 2 years, expecting consistency in current year – Entities such as $5M+ asset corporations, trusts, or Qualified Purchaser categories – Other qualifying categories include Series 7/65/82 holders or entity owners composed solely of accredited investors |
| Verification Process | Using third-party accredited verification service |
| Security Offered | SAFE Preferred Stocks |
| Form D Filing | SEC Form D to be filed within 15 days of first sale, with updates 30 days post final sale if extending |
| Closing Timeline | The offering will remain open until a closing is determined by the Company, based on investor commitments and subject to applicable regulatory requirements. No specific closing date has been established. Funds will be held in the Company’s bank account until closing. |
| Offering Expiration | The offering will remain open until such time as the Company determines to terminate or close the offering, subject to applicable securities laws and regulations. |
| Use Of Proceeds | • Construction of 8 million SF giga factory that includes IDM, AI, production lines, QC/QA, Smile Engineering Academy (SEA) etc. areas. • LYDIE TOWER, Housing, 2GU Davinci Resort & smart-city infrastructure • CapEx, R&D, marketing, and working capital |
| Transfer Restrictions | Securities are restricted and may not be resold unless registered under the Securities Act or an exemption is available; generally subject to a 6-month holding period under Rule 144 |
| Bad Actor Disqualification | The offering is subject to “bad actor” disqualification provisions; any involvement by disqualified persons will bar use of Reg D exemption |
24. INVESTOR QUALIFICATION
To ensure absolute operational efficiency and maintain strict adherence to SEC Rule 506(c) compliance, our executive desk operates a zero-broker friction policy. We only review, process, and respond to direct communications from institutional entities or individual principal partners who strictly fulfill the following regulatory thresholds and verification steps:
The inquiring party must fulfill the statutory definition of an Accredited Investor under SEC Rule 506(c) / Rule 501 parameters:
Because our structured initial tranche maintains a strict $1,000,000 ─ $1 million USD minimum investment requirement per investor, you must ensure your fund allocation models legally permit a minimum check size of this magnitude.
To protect privacy and automate compliance, MYDENTALWIG™ does not accept unverified financial documents directly. Investors must complete their verification through our official third-party compliance portal. Clicking the link below routes you directly to our dedicated setup, skipping all manual site navigation:
Once your background check is successfully completed, your attorney-certified Accreditation Verification Letter (PDF Format) will be generated. Qualified principals must email this final verification certificate alongside their technical due-diligence questions directly to our placement desk:
All non-compliant, unverified, or intermediate broker-dealer solicitations are programmatically filtered out. We will promptly respond to all inquiries matching these corporate standards.
INVEST
MYDENTALWIG began with a patented, FDA-cleared dental device and a fundamentally different approach to replacing missing teeth.
Today, we are building beyond the device — developing proprietary sensing and EI technologies designed to transform the mouth into an intelligent interface and connect continuous ingestion data with personalized health intelligence.
Our long-term vision is a vertically integrated, closed-loop ecosystem connecting human health, EI, research, advanced manufacturing and intelligent infrastructure.
A foundation already built.
A much larger opportunity ahead.
PROVEN FOUNDATION
TECHNOLOGY PLATFORM
LONG-TERM OPPORTUNITY
WHY NOW?
The convergence of EI, sensing, advanced manufacturing and personalized health is creating an opportunity to rethink how healthcare data is generated and used.
MYDENTALWIG is approaching that opportunity from an unconventional starting point: the mouth.
The place where we eat, drink, bite, chew and interact with the substances that enter our bodies every day.
THE INVESTMENT OPPORTUNITY
… with the objective of creating a closed-loop technology ecosystem that can expand far beyond the original dental device.
We’re building the infrastructure for a different kind of healthcare intelligence.
INVEST
© Copyright by My Dental Wig